MDT 8-K Current Reports
Medtronic plc - 137 current reports
Medtronic plc 8-K Report, Financial Results (Jun 3, 2026)
Medtronic plc (MDT) has filed an 8-K report on June 3, 2026, to announce its financial results for the fourth quarter and the full fiscal year 2026. The report primarily serves to furnish the earnings press release associated with these results. Investors should refer to Exhibit 99.1 for the detailed financial performance, including revenue, profitability, and segment-specific performance for the period. This filing is crucial for understanding Medtronic's recent operational and financial standing and for making informed investment decisions. While the 8-K itself is a procedural filing to report the release of financial information, the attached press release will contain the substantive data investors need. This typically includes key financial metrics, management commentary on performance drivers and outlook, and potentially updates on strategic initiatives or product developments. Investors are encouraged to review the full press release to grasp the complete picture of Medtronic's fiscal year 2026 performance and its trajectory moving forward.
Medtronic plc 8-K Report, Executive Changes (May 18, 2026)
Medtronic plc (MDT) has filed an 8-K report on May 18, 2026, to announce a significant leadership transition within its Neuroscience Portfolio. Brett Wall is departing from his role as Executive Vice President and President, Neuroscience Portfolio. While he will remain with the company until September 1, 2026, to ensure a smooth handover, his departure marks a change in leadership for this key division. Dr. Kweli Thompson, currently Senior Vice President and President of Cardiac Rhythm Management, will assume the leadership of the Neuroscience Portfolio starting June 1, 2026. Investors should monitor the performance and strategic direction of the Neuroscience Portfolio under Dr. Thompson's leadership.
Medtronic plc 8-K Report, Regulation FD Disclosure (Apr 27, 2026)
Medtronic plc (MDT) has disclosed a data security incident where an unauthorized third party accessed certain IT systems. The company identified the breach, took immediate containment measures, and engaged external cybersecurity experts to investigate. Based on the current investigation, Medtronic has not found any impact on its products, patient safety, customer relationships, manufacturing, distribution, or financial reporting. The company currently anticipates no material impact on its business or financial results from this incident. Investors should note that Medtronic has provided a statement on its website regarding this event, which is furnished as part of this 8-K filing. While the company has taken prompt action and currently assesses the impact as immaterial, ongoing monitoring and the full scope of the investigation will be crucial to watch for any potential future developments. The forward-looking statements disclaimer highlights inherent risks and uncertainties associated with such events.
Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 24, 2026)
Medtronic plc (MDT) announced an important regulatory milestone for its consolidated subsidiary, MiniMed Group, Inc. The U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation insulin pump. This clearance arrived several months ahead of schedule, enabling an earlier commercial launch for this significant product in the diabetes management market. The development of the MiniMed Flex was partially funded by Blackstone, and under their agreement, Medtronic will incur a one-time charge of $157 million in the fourth quarter of fiscal year 2026, impacting reported EPS by approximately $0.08 per share. This charge relates to future payments to Blackstone based on sales performance during the initial two years post-launch. Additionally, the previously disclosed initial public offering (IPO) of 10% of MiniMed will contribute an additional $0.04 per share dilution to Medtronic shareholders in the fourth quarter of fiscal year 2026. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downward to a range of $5.50 to $5.54, from the previous $5.62 to $5.66 range. The company's long-term outlook for fiscal year 2027, projecting high single-digit EPS growth, remains unchanged.
Medtronic plc 8-K Report, Financial Results (Feb 17, 2026)
Medtronic plc (MDT) has filed an 8-K report on February 17, 2026, to announce its third quarter fiscal year 2026 financial results. The primary purpose of this filing is to furnish the press release detailing these results, which were released on the same day. Investors should review the press release (Exhibit 99.1) for specific performance metrics, revenue figures, profitability, and any forward-looking statements or guidance provided by the company for the remainder of the fiscal year. This report serves as the official notification of the company's recent financial performance. While the 8-K itself is brief, it directs investors to the comprehensive financial data contained within the furnished press release. Key areas of interest for investors will likely include the performance of Medtronic's various business segments, comparisons to analyst expectations, and any commentary on the macroeconomic or industry-specific factors impacting the results. Understanding these details is crucial for assessing Medtronic's current financial health and future prospects.
Medtronic plc 8-K Report, Financial Results (Nov 18, 2025)
Medtronic plc (MDT) has filed a Form 8-K on November 18, 2025, to report its second quarter fiscal year 2026 financial results. The filing primarily consists of a press release containing these results, which is furnished as an exhibit. Investors should refer to the accompanying press release (Exhibit 99.1) for the detailed financial performance and operational highlights for the quarter ended November 17, 2025. While the 8-K itself does not provide the specific financial figures, it serves as the official notification of the release of this important information. Key metrics such as revenue, earnings per share (EPS), and segment performance, along with management's commentary on business outlook and strategic progress, will be found within the press release. Investors are encouraged to review this document thoroughly to understand Medtronic's current financial health and future prospects.
Medtronic plc 8-K Report, Executive Changes (Nov 3, 2025)
Medtronic plc announced on November 2, 2025, that its Executive Vice President, Enterprise Operations, Gregory L. Smith, will retire from the company effective December 2, 2025. Mr. Smith's departure marks a leadership transition within the company's operations segment. Investors should note that his retirement triggers specific provisions regarding his outstanding equity compensation, as detailed in the company's filings.
Medtronic plc 8-K Report, Bylaw Amendment (Oct 21, 2025)
Medtronic plc (MDT) filed an 8-K detailing the outcomes of its Annual General Meeting held on October 16, 2025. The primary focus of this report is the shareholder approval of significant amendments to the company's Articles of Association. These amendments, effective October 16, 2025, include modifications to Article 177 to enable the Board of Directors to capitalize non-distributable reserves for the creation of additional distributable reserves, and updates to the company's advance notice provisions for shareholder proposals. Beyond the governance-related changes, the meeting also saw shareholders overwhelmingly re-elect all twelve director nominees. Furthermore, investors ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026 and approved the compensation of named executive officers in advisory votes. The company also secured shareholder approval for renewing the Board's authority to issue shares and opt out of pre-emption rights, along with authorizing overseas market purchases of Medtronic ordinary shares. A capital reduction to create distributable reserves under Irish Law was also approved.
Medtronic plc 8-K Report, Material Agreement (Sep 29, 2025)
Medtronic plc (MDT) has filed an 8-K report detailing a significant debt offering and the redemption of existing notes. On September 29, 2025, an indirect wholly owned subsidiary, Medtronic, Inc., successfully issued €1.5 billion in aggregate principal amount of senior notes, split between 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045. These new notes are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The primary purpose of this offering is to refinance existing debt. Medtronic, Inc. expects to use the net proceeds of approximately €1.49 billion to repay Medtronic Luxco's 0.000% Senior Notes due 2025 and its 2.625% Senior Notes due 2025. Concurrently, Medtronic Luxco has redeemed all outstanding €500 million of its 2.625% Senior Notes due 2025, with this redemption being contingent on the successful completion of the new notes issuance. This strategic debt management indicates Medtronic's effort to optimize its capital structure and extend its debt maturity profile.
Medtronic plc 8-K Report, Regulation FD Disclosure (Sep 16, 2025)
Medtronic plc (MDT) has filed an 8-K detailing the pricing and issuance of new senior notes, alongside the redemption of existing notes. The company will issue €1.5 billion in aggregate principal amount of new senior notes, consisting of €750 million due 2030 at 2.950% and €750 million due 2045 at 4.200%. These new notes are guaranteed by Medtronic plc and Medtronic Luxco. The net proceeds from this offering are earmarked to repay Medtronic Luxco's maturing 0.000% and 2.625% Senior Notes due 2025. Specifically, Medtronic Luxco has elected to redeem all outstanding €500 million of its 2.625% Senior Notes due 2025 on September 29, 2025, at a price of 100% of the principal plus accrued interest. The redemption is contingent on the successful completion of the new notes issuance. This refinancing activity was previously factored into Medtronic's reiterated fiscal year 2026 adjusted earnings per share guidance.
Medtronic plc 8-K Report, Financial Results (Aug 19, 2025)
Medtronic plc (MDT) has filed a Form 8-K detailing its first quarter fiscal year 2026 financial results, announced via press release on August 19, 2025. While the specific financial figures are not detailed within this 8-K filing itself but rather in the furnished press release (Exhibit 99.1), this report signals the company's performance update for the period ending August 2025. Investors should refer to the separate earnings release for critical financial metrics such as revenue, earnings per share, and segment performance. In addition to the financial update, the company announced a significant change to its Board of Directors. Effective August 19, 2025, the Board's size has been expanded from 11 to 13 members with the appointment of two new directors, John Groetelaars and William Jellison. Both new directors will receive standard non-employee director compensation, including cash retainers and equity grants, as per the company's policy. Mr. Jellison has been appointed to newly formed Growth and Operations committees, while Mr. Groetelaars will serve on the Growth committee. These board changes, announced via a separate press release (Exhibit 99.2), aim to bolster the board's oversight and strategic direction.
Medtronic plc 8-K Report, Executive Changes (Jun 23, 2025)
Medtronic plc (MDT) announced a change to its Board of Directors, appointing Dr. Joon Lee as a new director. This appointment increases the size of the Board from 10 to 11 members, effective June 18, 2025. Dr. Lee will contribute to the company's strategic oversight by serving on both the Science and Technology Committee and the Compensation and Talent Committee. This addition to the Board signifies Medtronic's commitment to strengthening its governance and leveraging specialized expertise. Investors should note that Dr. Lee's compensation will follow the company's standard non-employee director compensation policy, including an annual cash retainer and equity grants. The filing confirms no related-party transactions or special arrangements concerning Dr. Lee's appointment, indicating a standard governance update.
Medtronic plc 8-K Report, Financial Results (May 21, 2025)
Medtronic plc (MDT) filed an 8-K on May 21, 2025, reporting its fourth quarter and full fiscal year 2025 financial results. While specific financial figures are not detailed in this 8-K, the release of this information suggests a review of the company's operational performance and financial condition. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial outcomes. Significantly, the filing also announced a major strategic shift: Medtronic intends to separate its Diabetes business into a new, standalone public company. This move indicates a focus on streamlining operations and potentially unlocking value for shareholders by allowing each business segment to operate with greater strategic flexibility. Additionally, the company disclosed a leadership change within its Cardiovascular Portfolio, with Sean Salmon departing and Skip Kiil assuming the role of EVP and President, Cardiovascular Portfolio, effective May 21, 2025. Mr. Salmon will remain with the company until September 2, 2025, and will receive severance in line with company policy.
Medtronic plc 8-K Report, Executive Changes (Mar 17, 2025)
Medtronic plc (MDT) announced a leadership transition within its finance department. Jennifer M. Kirk, the Global Controller and Principal Accounting Officer, has resigned effective May 2, 2025, to pursue a CEO role at a private company, Exubrion Therapeutics. Investors should note that Ms. Kirk's departure is not attributed to any disagreements regarding Medtronic's operations or policies. To ensure a seamless handover, Denise L. Blomquist, currently the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025. Ms. Blomquist brings extensive experience to the role, having been with Medtronic for 21 years in various finance positions. Her compensation will align with industry standards, including participation in the company's incentive and long-term incentive plans.
Medtronic plc 8-K Report, Financial Results (Feb 18, 2025)
Medtronic plc (MDT) has filed a Form 8-K with the SEC on February 18, 2025, to report its third quarter fiscal year 2025 financial results. The filing primarily serves to furnish the press release containing these results, which was issued on the same date. Investors should refer to the press release, provided as Exhibit 99.1, for detailed financial performance data, including revenue, earnings, and any forward-looking guidance or commentary provided by the company. While the 8-K itself is a brief procedural filing, the associated press release will contain the critical operational and financial metrics that investors will use to assess Medtronic's performance against expectations and to make informed investment decisions. Key areas to scrutinize in the press release will include segment performance, growth drivers, profitability trends, and management's outlook for the remainder of fiscal year 2025 and beyond.
Medtronic plc 8-K Report, Executive Changes (Jan 21, 2025)
Medtronic plc (MDT) has announced a significant leadership change with the appointment of Thierry Pieton as its new Executive Vice President and Chief Financial Officer (CFO), effective March 3, 2025. Mr. Pieton brings extensive global finance experience, including nearly 16 years at General Electric and most recently serving as CFO at Renault. This appointment signals a strategic move to leverage his operational finance expertise for Medtronic's future growth and financial stewardship. Investors should note the comprehensive compensation package designed to attract Mr. Pieton, which includes a substantial base salary, performance-based incentive plans, and significant long-term equity awards totaling $4.5 million in initial grants (including a $2 million LTIP award and a $2.5 million New Hire RSU). This investment in leadership underscores the company's commitment to strengthening its financial team. Additionally, the filing confirms Gary Corona's continued role as Interim CFO until Mr. Pieton's effective date, recognizing his contributions with a $1 million RSU grant.
Medtronic plc 8-K Report, Financial Results (Nov 19, 2024)
Medtronic plc filed an 8-K on November 19, 2024, to report its second quarter fiscal year 2025 financial results, as detailed in a press release furnished as Exhibit 99.1. This filing primarily serves as a notification mechanism for the market regarding the company's performance during the latest reported quarter. Investors should refer to the accompanying press release for the specific financial details, including revenue, earnings per share, and segment performance, which are crucial for assessing the company's operational health and strategic execution. While the 8-K itself is brief, it directs stakeholders to the comprehensive financial information within the press release. This release will contain management's commentary on the results, outlook for the remainder of the fiscal year, and potentially any significant business developments. Investors are advised to examine these details to understand the drivers of the reported financial outcomes and to evaluate Medtronic's trajectory relative to its guidance and industry peers.
Medtronic plc 8-K Report, Shareholder Vote Results (Oct 21, 2024)
Medtronic plc (MDT) filed an 8-K on October 21, 2024, detailing the outcomes of its 2024 Annual General Meeting of Shareholders held on October 17, 2024. The meeting saw strong shareholder support for all proposals presented, indicating alignment between management and its investors on key corporate governance matters. All ten director nominees were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor for FY2025 was ratified, and executive compensation received advisory approval. Furthermore, shareholders renewed the Board's authority to issue shares, opt out of pre-emption rights, and to conduct overseas market purchases of Medtronic ordinary shares. The substantial 'FOR' votes across all resolutions, with a quorum of over a majority of outstanding shares present, underscores robust shareholder confidence and engagement.
Medtronic plc 8-K Report, Financial Results (Aug 20, 2024)
Medtronic plc (MDT) has filed an 8-K report on August 20, 2024, furnishing a press release detailing its first-quarter fiscal year 2025 financial results. This filing is crucial for investors as it provides the latest performance data for the company. While the 8-K itself doesn't contain the detailed financial figures, it directs investors to the accompanying press release (Exhibit 99.1) for the specific revenue, profit, and segment performance numbers. Investors should review this press release to understand Medtronic's current financial health and operational achievements for the quarter ending in July 2024.
Medtronic plc 8-K/A Report, Executive Changes (Aug 16, 2024)
Medtronic plc (MDT) has filed an 8-K/A amendment to its previous filing, providing updated details on the compensatory arrangement for its interim Chief Financial Officer, Gary Corona. This amendment clarifies the financial incentives put in place following his appointment, which was previously announced. Investors should note the specific cash stipend and equity grant designed to compensate Mr. Corona during his interim role. The key takeaways for investors revolve around the financial terms of Mr. Corona's interim CFO position. These include a substantial bi-weekly cash stipend and a significant RSU grant, which are designed to incentivize and compensate him for taking on this critical role. While his base salary, target bonus, and existing long-term incentive grant remain unchanged, the new arrangements provide a clear picture of the additional compensation tied to his interim CFO responsibilities.
Medtronic plc 8-K Report, Executive Changes (Jun 26, 2024)
Medtronic plc announced a significant leadership change in its finance department via an 8-K filing on June 26, 2024. Karen L. Parkhill, Executive Vice President and Chief Financial Officer, has decided to resign from her position, with her departure effective August 2, 2024. This marks the end of her tenure with the company. In response to Ms. Parkhill's departure, Medtronic has appointed Gary Corona as the interim Chief Financial Officer, effective August 2, 2024. Mr. Corona currently serves as Senior Vice President, Global Financial Planning and Analysis and has been with Medtronic since January 2023. He brings extensive experience from his previous 26-year tenure at General Mills, Inc. The company has also furnished a press release detailing these changes, which is attached as an exhibit to the filing.
Medtronic plc 8-K Report, Executive Changes (Jun 4, 2024)
Medtronic plc (MDT) announced the retirement of Rob ten Hoedt, Executive Vice President and President of Global Regions, effective June 28, 2024. This departure marks a significant leadership change within the company's international operations. While the filing itself is brief, it signals the need for investors to monitor the transition process and the company's strategic adjustments in its global markets. Investors should pay close attention to any subsequent announcements regarding Mr. ten Hoedt's successor and the operational plans for the Global Regions segment moving forward.
Medtronic plc 8-K Report, Material Agreement (Jun 3, 2024)
Medtronic plc, through its indirect wholly owned subsidiary Medtronic, Inc., has successfully completed a significant debt offering, raising approximately €2.97 billion. This offering comprises four series of senior notes due in 2029, 2036, 2043, and 2053, with coupon rates ranging from 3.650% to 4.150%. These notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, providing an additional layer of credit support for investors. The net proceeds are intended for general corporate purposes, including the potential repayment of outstanding commercial paper and other existing indebtedness. This strategic move suggests Medtronic is actively managing its capital structure and may be refinancing existing debt, potentially at more favorable terms or extending its debt maturity profile. The company has applied to list these new notes on the New York Stock Exchange, enhancing their liquidity and accessibility for investors.
Medtronic plc 8-K Report, Financial Results (May 23, 2024)
Medtronic plc filed an 8-K on May 22, 2024, to announce its full-year and fourth-quarter fiscal year 2024 financial results. This filing primarily serves to attach the official press release detailing these results, which was issued on May 23, 2024. Investors should refer to the press release (Exhibit 99.1) for specific financial performance data, including revenue, profit margins, earnings per share, and guidance for the upcoming fiscal year. The 8-K itself does not contain the detailed financial figures but directs stakeholders to the comprehensive information provided in the accompanying press release.
Medtronic plc 8-K Report, Financial Results (Feb 20, 2024)
Medtronic plc announced its third-quarter fiscal year 2024 financial results on February 20, 2024. This 8-K filing primarily details operational changes and executive transitions alongside the financial results announcement. Investors should note the company's strategic decision to wind down and exit the ventilator business. This move will lead to the consolidation of remaining businesses within the Patient Monitoring and Respiratory Interventions units into a single operating unit. As a consequence of these operational shifts, Robert J. White, Executive Vice President and President of Medtronic’s Medical Surgical Portfolio, will be leaving the company effective April 26, 2024. His departure is classified as a termination without cause, and he will receive severance payments and benefits in line with Medtronic's established executive severance practices. While the 8-K itself doesn't provide the specific Q3 financial figures, it directs investors to the press release (Exhibit 99.1) for detailed results.
Medtronic plc 8-K Report, Corporate Update (Dec 6, 2023)
Medtronic plc (MDT) announced on December 6, 2023, that it has terminated its previously announced definitive agreements to acquire EOFlow Co. Ltd. The termination follows multiple alleged breaches of the agreements by EOFlow. Medtronic has stated that it does not believe any termination fee is payable under the terms of the agreements. This decision is significant as it halts a key strategic acquisition intended to bolster Medtronic's diabetes business. Importantly, Medtronic has clarified that this termination will not impact its previously issued fiscal year 2024 adjusted earnings per share guidance. The company remains committed to its automated insulin dosing product pipeline, including the development of a differentiated patch pump. Investors should note that this termination reflects Medtronic's disciplined approach to deal-making and its commitment to its strategic priorities, even when a transaction does not proceed as planned.
Medtronic plc 8-K Report, Financial Results (Nov 21, 2023)
Medtronic plc (MDT) filed an 8-K on November 21, 2023, to announce its second quarter fiscal year 2024 financial results. The primary purpose of this filing is to furnish the press release detailing these results, which were issued on the same date. Investors should review the furnished press release for comprehensive details on the company's performance during the quarter, including revenue, earnings, and any significant business updates or segment performance. This 8-K serves as the official notification of these results to the market.
Medtronic plc 8-K Report, Executive Changes (Oct 23, 2023)
This 8-K filing from Medtronic plc details the outcomes of their 2023 Annual General Meeting of Shareholders held on October 19, 2023. The most significant news for investors is the shareholder approval of the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan). This new plan will replace the existing 2014 Plan and makes available 30 million ordinary shares, with the first purchase period commencing January 1, 2024. Additionally, all director nominees were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024 was ratified, and executive compensation was approved on an advisory basis. The company also secured shareholder approval for the renewal of the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of its shares, which are important for strategic financial flexibility.
Medtronic plc 8-K Report, Financial Results (Aug 22, 2023)
Medtronic plc filed an 8-K on August 22, 2023, to furnish its press release announcing its first quarter fiscal year 2024 financial results. While the filing itself doesn't contain the detailed financial performance data, it directs investors to the accompanying press release (Exhibit 99.1) for this crucial information. Investors should refer to that press release for specifics on revenue, earnings, segment performance, and any forward-looking guidance provided by the company for the first quarter of FY2024.
Medtronic plc 8-K Report, Executive Changes (Jun 26, 2023)
Medtronic plc (MDT) announced a change to its Board of Directors, appointing Greg Lewis as a new director effective June 26, 2023. This appointment increases the size of the Board from 11 to 12 members. Mr. Lewis will also serve on the Audit committee and the Finance and Financial Risk committee, bringing his expertise to key oversight functions of the company. Investors should note that Mr. Lewis's appointment is part of the company's standard director compensation policy, and he will receive an annual cash retainer and an equity grant. The filing confirms there are no disqualifying arrangements or reportable transactions between Mr. Lewis and Medtronic. This is a routine governance update, but the addition of a director to specialized committees is a notable development for board oversight.
Medtronic plc 8-K Report, Financial Results (May 25, 2023)
Medtronic plc (MDT) filed an 8-K on May 25, 2023, primarily to furnish its full-year and fourth-quarter fiscal year 2023 financial results, as announced in their press release dated May 25, 2023. While the 8-K itself doesn't contain detailed financial figures, it serves as the official notification to investors that these results are now publicly available via the press release (Exhibit 99.1). Investors should refer to this press release for specific performance metrics, revenue figures, profitability, and any forward-looking guidance or commentary from management regarding the company's performance and outlook for the upcoming fiscal year.
Medtronic plc 8-K Report, Material Agreement (Mar 30, 2023)
Medtronic plc (MDT) announced on March 30, 2023, through its indirect wholly owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), the issuance of $2 billion in aggregate principal amount of senior notes. This offering comprises $1 billion of 4.250% Senior Notes due 2028 and $1 billion of 4.500% Senior Notes due 2033. The net proceeds, expected to be approximately $1.98 billion after expenses, are earmarked for the prepayment of a portion of Medtronic Luxco's Japanese-yen denominated term loan, which amounts to approximately $2.3 billion. This debt issuance represents a proactive move by Medtronic to refinance a specific tranche of its existing debt, likely to optimize its capital structure and potentially reduce interest expenses or alter its debt maturity profile. The notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc., providing additional security to investors. While the offering itself is not expected to have a material impact on interest expense, net, it signifies ongoing financial management and debt servicing strategies by the company.
Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 9, 2023)
Medtronic plc (MDT) filed an 8-K on March 9, 2023, to address an erroneous communication regarding the redemption of its 0.000% Senior Notes due 2025, issued by its subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco"). The company clarified that Medtronic Luxco has not issued any notice of redemption for these notes. This disclosure was made to correct misinformation that had been erroneously communicated to data providers like Bloomberg and subsequently disseminated more widely. Investors should be aware that this filing is purely for informational purposes to correct a factual error and does not indicate any changes to Medtronic's debt obligations or financial strategy related to these specific notes.
Medtronic plc 8-K Report, Shareholder Nominations (Mar 7, 2023)
This 8-K filing from Medtronic plc announces key dates and deadlines related to its 2023 Annual General Meeting of Shareholders (AGM). The AGM is scheduled for October 19, 2023, with a record date of August 25, 2023, for determining shareholders eligible to vote. This filing is crucial for investors as it sets the timelines for submitting shareholder proposals and director nominations. Notably, because the AGM date has shifted significantly from the previous year's anniversary, the previously announced deadlines for shareholder actions no longer apply. The company is providing updated timelines to ensure shareholders are aware of the requirements for presenting proposals or nominating directors, whether for inclusion in the proxy materials or for presentation directly at the meeting. Investors interested in actively participating in corporate governance through these avenues should pay close attention to the specified submission deadlines.
Medtronic plc 8-K Report, Financial Results (Feb 21, 2023)
Medtronic plc (MDT) filed an 8-K on February 21, 2023, to announce its third quarter fiscal year 2023 financial results. The filing itself is primarily a notification that a press release containing these results has been issued, and the press release is attached as an exhibit. Investors should refer to the press release (Exhibit 99.1) for detailed financial performance, including revenue, earnings, and segment-specific information. While the 8-K doesn't contain the specific numbers, it signals the release of crucial performance data for the quarter ending February 20, 2023. This information is vital for assessing Medtronic's current operational health, progress against its strategic goals, and potential implications for future financial performance and stock valuation. Investors are advised to review the accompanying press release for a comprehensive understanding of the reported results.
Medtronic plc 8-K Report, Shareholder Vote Results (Dec 13, 2022)
This 8-K filing from Medtronic plc details the outcomes of its 2022 Annual General Meeting of Shareholders held on December 8, 2022. The meeting served as a platform for shareholders to vote on key corporate governance matters, including the election of directors, ratification of the independent auditor, executive compensation, and authorities related to share issuance and repurchases. The overall results indicate strong shareholder support for the company's management and proposed actions. Key proposals, including the election of all eleven director nominees and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023, received overwhelming approval. Shareholder approval was also granted for the compensation of named executive officers and for renewing the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of Medtronic ordinary shares. The significant turnout and affirmative votes demonstrate shareholder confidence in Medtronic's leadership and strategic direction.
Medtronic plc 8-K Report, Financial Results (Nov 22, 2022)
Medtronic plc filed an 8-K on November 22, 2022, to announce its second quarter fiscal year 2023 financial results. This filing primarily serves to furnish the press release containing these results, which was issued on November 22, 2022. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial performance and operational updates for the quarter ending October 28, 2022. The 8-K itself does not contain new quantitative financial data but directs stakeholders to the primary source of this information. The key takeaway for investors is that this filing is a standard procedure to officially disclose their quarterly earnings. While the 8-K provides the context of the filing, the substantive financial details, including revenue, earnings per share, segment performance, and forward-looking guidance (if any), are contained within the accompanying press release. Investors are strongly advised to review the press release to understand Medtronic's financial health and strategic direction for the second quarter.
Medtronic plc 8-K Report, Material Agreement (Sep 21, 2022)
Medtronic plc (MDT) announced the closing of a significant debt offering through its indirect wholly owned subsidiary, Medtronic Global Holdings S.C.A. (Medtronic Luxco). The company successfully issued €3.5 billion in aggregate principal amount of senior notes across four tranches with varying maturities and interest rates: 2.625% Senior Notes due 2025, 3.000% Senior Notes due 2028, 3.125% Senior Notes due 2031, and 3.375% Senior Notes due 2034. These notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. The primary purpose of this offering is to refinance existing debt, specifically Medtronic Luxco's outstanding 0.00% Senior Notes due 2022 and its 0.375% and 0.00% Senior Notes due 2023, which are nearing maturity. The net proceeds, estimated at approximately €3.47 billion after expenses, will also be allocated for general corporate purposes. Medtronic has reiterated that its fiscal year 2023 adjusted earnings per share guidance, previously issued, already accounts for the financial impact of this offering and its use of proceeds. The company has applied to list these new notes on the New York Stock Exchange.
Medtronic plc 8-K Report, Financial Results (Aug 23, 2022)
Medtronic plc (MDT) has filed an 8-K report on August 23, 2022, to announce its financial results for the first quarter of its fiscal year 2023. The press release, furnished as Exhibit 99.1, provides details on the company's performance during this period. Investors should refer to this press release for the specific financial figures, including revenue, earnings per share, and any segmental performance data, which are crucial for assessing the company's ongoing operational health and future prospects. While the 8-K itself does not contain the detailed financial results, it serves as the official notification that these results have been released. The information within the accompanying press release will be key for understanding any year-over-year or sequential changes in Medtronic's financial condition, profitability, and operational efficiency. Investors are encouraged to review the full press release for a comprehensive understanding of the Q1 FY2023 performance.
Medtronic plc 8-K Report, Executive Changes (Jun 27, 2022)
Medtronic plc announced a change to its Board of Directors, effective June 27, 2022. The size of the Board has been increased from 10 to 11 members, and Lidia L. Fonseca has been appointed as a new director. This appointment is a standard governance update, bringing new expertise to the company's leadership. Investors should note that Ms. Fonseca will participate in the company's standard director compensation plan, including cash retainers and equity grants. Her appointment to key committees, Science and Technology and Compensation, suggests a focus on innovation and executive remuneration oversight.
Medtronic plc 8-K Report, Financial Results (May 26, 2022)
Medtronic plc filed an 8-K on May 26, 2022, primarily to disclose its fourth quarter and full-year fiscal year 2022 financial results and a significant strategic partnership. In addition to reporting financial outcomes for FY2022, the company announced a joint venture with DaVita Inc. to form a new, independent kidney care-focused medical device company, referred to as "NewCo". This transaction involves Medtronic contributing its entire Renal Care Solutions (RCS) business, which generated $325 million in FY2022 revenue, to NewCo. From an investor's perspective, the formation of NewCo is structured to have a minimal impact on Medtronic's adjusted earnings per share in the near term (FY2023 and a few subsequent years). Medtronic and DaVita will share equal equity in NewCo, with DaVita providing a cash payment and non-cash assets, plus potential contingent consideration tied to milestones, which could total up to $400 million in value for Medtronic. Both companies will also contribute $200 million in cash to launch NewCo. The company plans to exclude the RCS revenue from its organic revenue growth calculations for a specified period post-transaction, which is expected to close in calendar year 2023.
Medtronic plc 8-K Report, Material Agreement (May 2, 2022)
Medtronic plc (MDT) announced on May 2, 2022, through its subsidiary Medtronic Global Holdings S.C.A., the entry into a 364-day unsecured term loan agreement with Mizuho Bank, Ltd. for up to JPY 300,000,000,000 (approximately $2.3 billion USD based on exchange rates at the time). This facility, which was undrawn at closing, is intended to fund general corporate purposes, specifically the redemption of Medtronic's outstanding $1,900 million 3.500% Senior Notes due 2025 and Medtronic Luxco's $368 million 3.350% Senior Notes due 2027. The company expects these debt refinancing actions to positively impact its fiscal year 2023 interest expense, although this benefit will be partially offset by increased U.S. tax expenses and a generally higher global interest rate environment. Investors should note that the redemption dates for these notes are set for May 17, 2022, and June 1, 2022, respectively. Medtronic plans to provide updated financial guidance for FY2023 during its upcoming Q4 FY2022 earnings call.
Medtronic plc 8-K Report, Financial Results (Feb 22, 2022)
Medtronic plc filed an 8-K on February 22, 2022, to report its third quarter fiscal year 2022 financial results. This filing primarily serves as a notification and attachment of the press release detailing these results. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive details on the company's performance during the quarter ending February 21, 2022. The key takeaway for investors is that this 8-K directs them to the official source of the Q3 FY2022 earnings announcement. While the 8-K itself is procedural, the underlying financial results within the press release will contain critical information such as revenue, earnings per share (EPS), segment performance, and guidance, which are vital for assessing Medtronic's operational health and future prospects.
Medtronic plc 8-K Report, Executive Changes (Dec 16, 2021)
Medtronic plc (MDT) announced the upcoming retirement of Dr. Richard Kuntz, Senior Vice President and Chief Medical and Scientific Officer, effective April 29, 2022. Dr. Kuntz has had a long and distinguished career at Medtronic, serving on the executive committee since 2005, and a significant 40-year career in medicine as an interventional cardiologist. While this filing is primarily administrative, the departure of a long-tenured executive like Dr. Kuntz is noteworthy for investors. His role has been critical in bridging clinical practice with scientific and medical strategy within the company. Investors may wish to monitor the company's succession planning and the strategic direction of its medical and scientific affairs under new leadership.
Medtronic plc 8-K Report, Regulation FD Disclosure (Dec 15, 2021)
Medtronic plc (MDT) announced on December 15, 2021, that it received a warning letter from the U.S. Food and Drug Administration (FDA) concerning its Northridge, California facility. While the company is actively addressing the FDA's concerns and working towards comprehensive resolutions, this development has led to revised revenue expectations specifically for its Diabetes business. Medtronic now anticipates a high-single digit decline for its Diabetes business in the third fiscal quarter and a mid-single digit decline for the full fiscal year 2022. This represents a downward revision from previous guidance. Importantly, the company currently does not expect this issue to materially impact its overall total company organic revenue growth and adjusted earnings per share guidance for fiscal year 2022. However, potential impacts on fiscal year 2023 revenue growth are being modeled, with preliminary estimates ranging from less than 0.5 percentage points to approximately 1 percentage point of growth reduction, depending on various scenarios.
Medtronic plc 8-K Report, Material Agreement (Dec 14, 2021)
Medtronic plc (MDT) filed an 8-K on December 14, 2021, detailing two key events. The first, under Item 1.01, announces the execution of an amendment to its credit agreement. This amendment extends the maturity date of the credit facility by one year to December 12, 2026, removes limits on future maturity extensions, and updates interest rate benchmarks to reflect the phasing out of LIBOR. Importantly, it also reduces the interest rate margins and commitment fees, making the company's borrowing costs potentially lower. The second significant event, under Item 5.07, covers the outcomes of Medtronic's 2021 Annual General Meeting of Shareholders. Key resolutions passed include the election of all ten director nominees, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation (on an advisory basis). Additionally, shareholders overwhelmingly approved the new 2021 Long Term Incentive Plan, renewed the board's authority to issue shares and opt out of pre-emption rights, and authorized overseas market purchases of company shares. These results indicate strong shareholder support for the company's governance and incentive structures.
Medtronic plc 8-K Report, Financial Results (Nov 23, 2021)
Medtronic plc (MDT) filed an 8-K on November 23, 2021, primarily to furnish a press release detailing its financial results for the second quarter of fiscal year 2022. This filing serves as the official communication channel for the company's performance updates. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive details on revenue, earnings, segment performance, and any forward-looking statements or guidance provided by management. The 8-K itself does not contain the detailed financial statements but points to the press release as the source of this information. Key information to extract from the press release would include the company's top-line and bottom-line performance relative to analyst expectations and prior periods, as well as commentary on the performance of Medtronic's various business segments (e.g., Cardiovascular, Medical Surgical, Neuroscience, Diabetes). Investors will be looking for trends, growth drivers, and any potential headwinds or tailwinds that may impact future financial performance. The accompanying press release is crucial for understanding the operational and financial health of Medtronic during the reported quarter.
Medtronic plc 8-K Report, Regulation FD Disclosure (Oct 15, 2021)
Medtronic plc (MDT) filed an 8-K on October 14, 2021, to provide an important update on its SPYRAL HTN-ON MED clinical study for its Symplicity™ Renal Denervation System. The study aims to lower blood pressure in hypertensive patients on medication. The independent data safety monitoring board (DSMB) has reviewed prespecified interim data and recommended that the trial continue enrollment as planned until the full sample size is reached. This indicates that while the interim results were not compelling enough for early trial stoppage, they were positive enough to warrant continued enrollment without modification. This update is significant as Medtronic anticipates the renal denervation market to become a multi-billion dollar opportunity, with projected global revenues of over $500 million by 2026 and $2-3 billion by 2030. Despite the ongoing nature of the ON MED study, the company reiterated that this announcement does not affect its fiscal year 2022 revenue and EPS guidance, nor its long-range financial targets for organic revenue growth of 5%+ and adjusted EPS growth of 8%+. Management expresses confidence in the renal denervation program and its overall outlook.
Medtronic plc 8-K Report, Regulation FD Disclosure (Sep 10, 2021)
Medtronic plc (MDT) has issued an 8-K filing to provide an update on its SPYRAL HTN-ON MED clinical study, which evaluates the Symplicity™ Renal Denervation System for hypertension. The company anticipates a prespecified interim data analysis by an independent monitoring board in late October. The outcome of this analysis, specifically whether the primary endpoint achieves statistical significance, will determine the next steps for the study. If the interim analysis shows statistical significance, enrollment in the ON MED study will be stopped, and the data will be prepared for presentation at the Transcatheter Cardiovascular Therapeutics Conference (TCT) in early November. However, due to the timing of the data analysis, the study will not be listed among TCT's late-breaking clinical trials. Medtronic is working with the Cardiovascular Research Foundation (CRF) to ensure the data is presented at TCT if the significance threshold is met. If the primary endpoint is not statistically significant at the interim look, the trial will continue to its full sample size.
Medtronic plc 8-K Report, Financial Results (Aug 24, 2021)
Medtronic plc (MDT) filed an 8-K on August 24, 2021, to report its first quarter fiscal year 2022 financial results. This filing primarily serves to furnish the press release announcing these results, which provides investors with timely information on the company's performance. The key takeaway for investors is access to Medtronic's most recent financial performance data for the quarter ended August 2021. While the 8-K itself doesn't contain the detailed financial statements, it directs investors to the press release (Exhibit 99.1) for specifics on revenue, earnings, and other operational metrics. Investors should review this press release to understand the company's top-line growth, profitability, and any forward-looking guidance provided by management.